131I-rituximab for Relapsed or Refractory Follicular or Mantle Cell Lymphoma
Status:
Unknown status
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
Follicular lymphoma (FL) and mantle cell lymphoma (MCL) are rare lymphomas which consist of
less than 5% of non-Hodgkin lymphoma in Korea. Although FL with histologic grade 1 or 2 has
relatively good prognosis, continual treatment is needed due to frequent relapse. FL with
histologic grade 3 has poor prognosis similar to that of diffuse large B cell lymphoma.
Meanwhile, the response rate to systemic chemotherapy in MCL is low, so the treatment of
relapsed MCL is challenging. So we investigate the efficacy of radioimmunotherapy using
131I-rituximab in refractory or relapsed patients with FL or MCL